Matrix Metalloproteinases and Temporomandibular Joint Disorder: A Review of the Literature

Temporomandibular disorders (TMD) are progressive degenerative disorders that affect the components of the temporomandibular joint (TMJ), characterized by pain and limitations in function. Matrix metalloproteinases (MMP) are enzymes involved in physiological breakdown of tissue that can have a pathological effect from an increase in activity during inflammation. A PubMed search of the current literature (within the past 10 years) was conducted to identify human studies involving matrix metalloproteinases activity in TMJ components of patients with TMD. Two separate searches results in 34 studies, six of which met inclusion criteria. Immunohistochemistry and gene analysis were used to evaluate MMP expression in the study groups. This review showed the strongest evidence for involvement of MMP-1, MMP-2, and MMP-9 in TMD; however, limitations included low sample sizes and a lack of recent clinical studies. Future research with more definitive conclusions could allow for additional pharmaceutical targets in MMP when treating patients with temporomandibular disorders.

[1]  Kyriacos A Athanasiou,et al.  Temporomandibular Joint Disorders: A Review of Etiology, Clinical Management, and Tissue Engineering Strategies , 2015 .

[2]  K. Pai,et al.  Condylar Changes and Its Association with Age, TMD, and Dentition Status: A Cross-Sectional Study , 2011, International journal of dentistry.

[3]  F. Machuron,et al.  Pre‐operative parafunctional or dysfunctional oral habits are associated with the temporomandibular disorders after orthognathic surgery: An observational cohort study , 2018, Journal of oral rehabilitation.

[4]  P. Breton,et al.  Condylar resorption after orthognathic surgery: A systematic review. , 2016, Revue de stomatologie, de chirurgie maxillo-faciale et de chirurgie orale.

[5]  K. Nakagawa,et al.  Expression of matrix metalloproteinase-2 and -9 in synovial fluid of the temporomandibular joint accompanied by anterior disc displacement. , 2001, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[6]  K. Ueki,et al.  Expression of matrix metalloproteinases and aggrecanase in the synovial fluids of patients with symptomatic temporomandibular disorders. , 2006, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[7]  C. Overall,et al.  Matrix metalloproteinase processing of signaling molecules to regulate inflammation. , 2013, Periodontology 2000.

[8]  A. Todorović,et al.  Association of Functional Polymorphisms in Matrix Metalloproteinase-9 and Glutathione S-Transferase T1 Genes with Temporomandibular Disorders. , 2015, Journal of oral & facial pain and headache.

[9]  M. Takigawa,et al.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids of patients with temporomandibular joint osteoarthritis. , 2000, Journal of orofacial pain.

[10]  D. Laskin.  Arthroscopy Versus Arthrocentesis for Treating Internal Derangements of the Temporomandibular Joint. , 2018, Oral and maxillofacial surgery clinics of North America.

[11]  C. H. Wilkes,et al.  Internal derangements of the temporomandibular joint. Pathological variations. , 1989, Archives of otolaryngology--head & neck surgery.

[12]  L. Rodella,et al.  Platelet-Rich Plasma in Treatment of Temporomandibular Joint Dysfunctions: Narrative Review , 2019, International journal of molecular sciences.

[13]  T. Kirita,et al.  MMP-3 activation is a hallmark indicating an early change in TMJ disorders, and is related to nitration. , 2009, International journal of oral and maxillofacial surgery.

[14]  C. Hansch,et al.  Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs. , 2007, Bioorganic & medicinal chemistry.

[15]  K. Kurita,et al.  Matrix metalloproteinase-2 in synovial lavage fluid of patients with disorders of the temporomandibular joint. , 2001, The British journal of oral & maxillofacial surgery.

[16]  G. Musumeci,et al.  An Ex Vivo Study on Immunohistochemical Localization of MMP-7 and MMP-9 in Temporomandibular Joint Discs with Internal Derangement , 2013, European journal of histochemistry : EJH.

[17]  M. Azevedo,et al.  Immunohistochemical expression of matrix metalloprotease-2 and matrix metalloprotease-9 in the disks of patients with temporomandibular joint dysfunction. , 2015, Journal of Oral Pathology & Medicine.

[18]  S. Adams,et al.  Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes , 2018, Molecular Cancer Therapeutics.

[19]  D. Haas,et al.  Pharmacotherapy in Temporomandibular Disorders: A Review. , 2017, Journal.

[20]  R. Secolin,et al.  Association of matrix metalloproteinase gene polymorphism with temporomandibular joint degeneration. , 2011, European journal of oral sciences.

[21]  T. Salo,et al.  Matrix metalloproteinases in mild and severe temporomandibular joint internal derangement synovial fluid. , 2001, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[22]  Jing Wang,et al.  Matrix Metalloproteinases: A Review of Their Structure and Role in Systemic Sclerosis , 2012, Journal of Clinical Immunology.

[23]  I. Căruntu,et al.  Matrix metalloproteinases involvement in pathologic conditions. , 2010, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.

[24]  W. Stetler-Stevenson,et al.  Immunolocalization of gelatinase-A (matrix metalloproteinase-2) in damaged human temporomandibular joint discs. , 1999, Archives of oral biology.

[25]  X. Long,et al.  Up-regulation of vascular endothelial growth factor in synovial fibroblasts from human temporomandibular joint by hypoxia. , 2007, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[26]  R. Poluha,et al.  Temporomandibular joint disc displacement with reduction: a review of mechanisms and clinical presentation , 2019, Journal of applied oral science : revista FOB.

[27]  A. Raustia,et al.  MMP-3 and -8 expression is found in the condylar surface of temporomandibular joints with internal derangement. , 2005, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[28]  S. Fujita,et al.  The localization of matrix metalloproteinase-3 and tenascin in synovial membrane of the temporomandibular joint with internal derangement. , 2008, Oral diseases.

[29]  M. Olandoski,et al.  Expression of MMP-13 in human temporomandibular joint disc derangement and osteoarthritis , 2018, Cranio : the journal of craniomandibular practice.

[30]  E. Mojs,et al.  Is there a relationship between psychological factors and TMD? , 2019, Brain and behavior.

[31]  A. Goss,et al.  Matrix metalloproteinase and tissue inhibitor of metalloproteinase in serum and lavage synovial fluid of patients with temporomandibular joint disorders. , 2000, The British journal of oral & maxillofacial surgery.

[32]  X. Long,et al.  Association between polymorphism of MMP-1 promoter and the susceptibility to anterior disc displacement and temporomandibular joint osteoarthritis. , 2015, Archives of oral biology.

[33]  R. Vandenbroucke,et al.  Is there new hope for therapeutic matrix metalloproteinase inhibition? , 2014, Nature Reviews Drug Discovery.

[34]  Y. Gan,et al.  Current Understanding of Pathogenesis and Treatment of TMJ Osteoarthritis , 2015, Journal of dental research.